Human respiratory beta coronavirus are emerging causes for Public Health Emergencies of International Concern (PHEIC). SARS-CoV2 is circulating worldwide since November 2019. We review here the cardiovascular morbidity and mortality in COVID-19, and data supporting the role for dysregulation of the RAS counterregulatory axis due to binding of SARS-CoV2 S protein to ACE2 receptor. Since this counterregulatory axis provides benefits not only on the cardiovascular front but also in acute lung injury, we speculate on potential use of ACE inhibitors and AT₁R blockers in critically ill COVID-19 patients, and report current evidences.

In this study, we successfully obtained a 2Mg-Fe mixture through mechanical alloying (MA) and processed it via accumulative roll bonding (ARB) (MA+ARB). Our primary focus was to analyze the impact of ambient air exposure while also evaluating the processing route. Some powder samples were exposed to air for 12 months before undergoing ARB processing. The Mg samples obtained after ARB processing exhibited a (002)-type texture. Our results demonstrate that all samples, including those processed via ARB, could rapidly absorb hydrogen within a matter of minutes, despite considerable differences in surface area between powders and rolled samples. ARB-processed samples reached approximately 60% of their maximum acquired capacity within just 24 minutes, compared to powders stored for a year which took 36 minutes. Also, the desorption temperatures were lower than those of MgH2. The absorption and desorption kinetics remained fast even after prolonged exposure to air. Although there were minor variations in capacities, our overall findings are promising since scalable techniques such as ARB have the potential to produce hydrogen storage materials that are both safe and cost-effective in a highly competitive market.

Diabetic kidney disease (DKD) is the major cause of chronic kidney disease (CKD) and increases the risk of cardiovascular events. Hemodynamic, inflammatory and metabolic factors, which share the convergent pathway of fibrosis, are considered to involve in the pathogenesis of DKD. In spite of the emerging of angiotensin receptors blockers (ARBs)/ angiotensin converting enzyme inhibitor (ACEI), sodium-glucose cotransporter 2 (SGLT2) inhibitors, and nonsteroidal mineralocorticoid receptors antagonists (NS-MRAs), current therapies still couldn’t arrest the progression of DKD. Glucagon like peptide 1 receptor agonists (GLP-1RAs) are promising agents to play renoprotective roles in slowing the progression of DKD. Based on the treatment of heart failure, combined use of drugs is recommended for DKD rather than single use. Unearthing the mechanisms underlying DKD is urgent to investigate the management of DKD. Here, we elaborate on the potential mechanisms and the current therapies of DKD. We also discuss the additional value of the combined use of these drugs for DKD to establish novel concepts of treatment.

Renal artery thrombosis is a sporadic serious clinical condition which potentially cause renal infarction. Diagnosis of renal infarction can be delayed or missed due to non specific clinical presentation and overlapping appearance of medical and surgical phenomena. Early diagnosis supported by biochemical and radiological findings while appropriate management potentially improve morbidity and mortality. Persistent abdominal or flank pain with raised LDH and proteinuria on background of thromboembolism risk factors supports the diagnosis. Despite the rarity of the disease rapid identification with prompt medical or endovascular intervention could prevent irreversible renal parenchymal damage.